- Home
- BCAB vs HYFT Comparison
BCAB vs HYFT Comparison
Compare BCAB & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | HYFT |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 80.8M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCAB | HYFT |
|---|---|---|
| Price | $0.66 | $1.69 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 374.6K |
| Earning Date | 11-13-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,019,110.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.46 |
| 52 Week Low | $0.24 | $0.27 |
| 52 Week High | $1.43 | $3.25 |
Technical Indicators
Market Signals| Indicator | BCAB | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | N/A |
| Support Level | $0.74 | N/A |
| Resistance Level | $0.83 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 14.83 | 0.00 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.